Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

13.39
-0.5050-3.63%
Volume:12.52K
Turnover:167.10K
Market Cap:2.34B
PE:5.05
High:13.70
Open:13.70
Low:13.10
Close:13.90
52wk High:19.50
52wk Low:11.51
Shares:174.43M
Float Shares:104.00M
Volume Ratio:0.99
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.65
EPS(LYR):0.2000
ROE:46.90%
ROA:-0.81%
PB:1.90
PE(LYR):66.95

Loading ...

Press Release: UKG Agrees to Acquire Inova Payroll

Dow Jones
·
Dec 13, 2025

Tenaya Therapeutics Announces Proposed Public Offering

GlobeNewswire
·
Dec 12, 2025

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

GlobeNewswire
·
Dec 12, 2025

ADP Unveils Lyric HCM in Australia and New Zealand

prnewswire
·
Dec 11, 2025

HUTCHMED (00013): TAZVERIK® Included in the First National Commercial Health Insurance Innovative Drug List

Stock News
·
Dec 08, 2025

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

GlobeNewswire
·
Dec 05, 2025

AI-Powered Event Notifications Might Change the Case for Investing in Paychex (PAYX)

Simply Wall St.
·
Dec 01, 2025

HUTCHMED (00013) to Present Clinical Data at 2025 ESMO Asia Congress and ASH Annual Meeting

Stock News
·
Nov 27, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
Nov 19, 2025

New Dayforce Report Uncovers America’s Growing Retirement Divide

GlobeNewswire
·
Nov 18, 2025

HUTCHMED (00013) Narrows YTD Gain to 5%: When Will the "Bull Market Misser" Rebound?

Stock News
·
Nov 12, 2025

Orient Securities Maintains "Buy" Rating on HUTCHMED (00013), Highlights Innovative ATTC Platform

Stock News
·
Nov 10, 2025

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire
·
Nov 09, 2025

CICC Remains a Buy on HUTCHMED (China) (HCM)

TIPRANKS
·
Nov 08, 2025

CICC Maintains Outperform Rating on HUTCHMED (00013) with Target Price of HK$30

Stock News
·
Nov 07, 2025

HUTCHMED Completes Enrollment for Global Phase 3 Study of Lung Cancer Combination Therapy

MT Newswires Live
·
Nov 05, 2025

HUTCHMED (00013) Completes Patient Enrollment for Global Phase III SAFFRON Study Evaluating ORPATHYS® (Savolitinib) and TAGRISSO® (Osimertinib) Combination Therapy in MET-Overexpressed/Amplified NSCLC Post-TAGRISSO® Progression

Stock News
·
Nov 05, 2025

Cytokinetics to Participate in November Investor Conferences

GlobeNewswire
·
Nov 05, 2025

HUTCHMED (00013.HK) Rises Over 3%

Deep News
·
Nov 04, 2025

Hutchmed highlights pipeline, business progress at R&D Updates event

TIPRANKS
·
Nov 03, 2025